This inventor holds 2 USPTO granted patents and 3 published patent applications. Top assignees: Shenzhen Institute of Geriatrics, The Second People's Hospital of Shenzhen (Shenzhen Institute of Geriatrics), Other. Active years: 2023-2024.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2023-2024
Title: Zhiyue Li: Innovator in Pharmaceutical Chemistry
Introduction
Zhiyue Li is a prominent inventor based in Shenzhen, China. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of novel compounds with potential therapeutic applications. With a total of 2 patents, his work showcases innovative approaches to drug design and synthesis.
Latest Patents
Zhiyue Li's latest patents include a structural analog of Cyclotheonellazole A and a method for preparing the natural bioactive peptide Tubulysin U. The first patent provides a compound with a specific structure that demonstrates excellent protease inhibitory activity, indicating strong potential for pharmaceutical applications. The second patent outlines a detailed preparation method for Tubulysin U, involving multiple chemical reactions to yield the target product.
Career Highlights
Throughout his career, Zhiyue Li has worked at notable institutions, including the Second People's Hospital of Shenzhen, which is part of the Shenzhen Institute of Geriatrics. His research has focused on synthesizing compounds that can lead to advancements in medical treatments.
Collaborations
Zhiyue Li has collaborated with esteemed colleagues such as Zhengzhi Wu and Bohua Long. These partnerships have contributed to the success of his research and the development of innovative solutions in the pharmaceutical industry.
Conclusion
Zhiyue Li's contributions to pharmaceutical chemistry through his patents and collaborative efforts highlight his role as an influential inventor. His work continues to pave the way for advancements in drug development and therapeutic applications.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile